Market closedNon-fractional
Ginkgo Bioworks/DNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Ginkgo Bioworks
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.
Ticker
DNA
Sector
Basic Materials
Trading on
NYSE
Industry
Chemicals
Headquarters
Boston, United States
Employees
1,218
Website
www.ginkgobioworks.com
Ginkgo Bioworks Metrics
BasicAdvanced
$750M
Market cap
-
P/E ratio
-$0.43
EPS
1.42
Beta
-
Dividend rate
Price and volume
Market cap
$750M
Beta
1.42
Financial strength
Current ratio
5.342
Quick ratio
5.117
Long term debt to equity
23.752
Total debt to equity
23.752
Interest coverage (TTM)
-7,484.85%
Management effectiveness
Return on assets (TTM)
-21.76%
Return on equity (TTM)
-65.81%
Valuation
Price to revenue (TTM)
3.172
Price to book
0.74
Price to tangible book (TTM)
0.85
Price to free cash flow (TTM)
-2.054
Growth
Revenue change (TTM)
-46.49%
Earnings per share change (TTM)
-55.59%
3-year revenue growth (CAGR)
27.95%
3-year earnings per share growth (CAGR)
57.94%
What the Analysts think about Ginkgo Bioworks
Analyst Ratings
Majority rating from 7 analysts.
Ginkgo Bioworks Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$38M
9.22%
Net income
-$166M
-21.60%
Profit margin
-437.73%
-28.22%
Ginkgo Bioworks Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.09
-$0.16
-$0.11
-$0.08
-
Expected
-$0.08
-$0.09
-$0.10
-$0.08
-$0.08
Surprise
6.78%
86.67%
13.79%
-4.00%
-
Ginkgo Bioworks News
AllArticlesVideos
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA)
PRNewsWire·3 days ago
Syngenta collaborates with Ginkgo Bioworks to enable faster launch of innovative biologicals
Business Wire·2 weeks ago
Syngenta collaborates with Ginkgo Bioworks to enable faster launch of innovative biologicals
PRNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ginkgo Bioworks stock?
Ginkgo Bioworks (DNA) has a market cap of $750M as of July 27, 2024.
What is the P/E ratio for Ginkgo Bioworks stock?
The price to earnings (P/E) ratio for Ginkgo Bioworks (DNA) stock is 0 as of July 27, 2024.
Does Ginkgo Bioworks stock pay dividends?
No, Ginkgo Bioworks (DNA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Ginkgo Bioworks dividend payment date?
Ginkgo Bioworks (DNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Ginkgo Bioworks?
Ginkgo Bioworks (DNA) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Ginkgo Bioworks stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.